TB Research

Faculty Opinions recommendation of Vitamin D supplements for prevention of tuberculosis infection and disease.

Anthony Harries, Kudakwashe C Takarinda

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2020-09

Abstract

D metabolites support innate immune responses to Mycobacterium tuberculosis. Data from phase 3, randomized, controlled trials of vitamin D supplementation to prevent tuberculosis infection are lacking. METHODS-We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT) to receive a weekly oral dose of either 14,000 IU of vitamin D 3 or placebo for 3 years. The primary outcome was a positive QFT result at the 3-year follow-up, expressed as a proportion of children. Secondary outcomes included the serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events. RESULTS-A total of 8851 children underwent randomization: 4418 were assigned to the vitamin D group, and 4433 to the placebo group; 95.6% of children had a baseline serum 25(OH)D level of less than 20 ng per milliliter. Among children with a valid QFT result at the end

MeSH terms

  • Medicine
  • Placebo
  • Vitamin D and neurology
  • Tuberculosis
  • Internal medicine
  • Confidence interval
  • Liter
  • Rate ratio
  • Vitamin
  • vitamin D deficiency
  • Randomized controlled trial
  • Randomization
  • Mycobacterium tuberculosis
  • Incidence (geometry)
  • Gastroenterology
  • Immunology